These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 14983955)

  • 1. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).
    Roobol MJ; Kirkels WJ; Schröder FH
    BJU Int; 2003 Dec; 92 Suppl 2():48-54. PubMed ID: 14983955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).
    Beemsterboer PM; Kranse R; de Koning HJ; Habbema JD; Schröder FH
    Int J Cancer; 1999 Aug; 84(4):437-41. PubMed ID: 10404100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer.
    Berenguer A; Luján M; Páez A; Santonja C; Pascual T
    BJU Int; 2003 Dec; 92 Suppl 2():33-8. PubMed ID: 14983952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.
    van der Cruijsen-Koeter IW; van der Kwast TH; Schröder FH
    J Natl Cancer Inst; 2003 Oct; 95(19):1462-6. PubMed ID: 14519752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; de Vries SH; Cruijsen-Koeter Iv; van der Kwast TH; Schröder FH;
    Prostate; 2006 May; 66(6):625-31. PubMed ID: 16388507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; van den Bergh RC; Wolters T; Schröder FH
    Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).
    Kranse R; Beemsterboer P; Rietbergen J; Habbema D; Hugosson J; Schröder FH
    Prostate; 1999 Jun; 39(4):316-22. PubMed ID: 10344223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European randomized study of screening for prostate cancer--the Rotterdam pilot studies.
    Shröder FH; Damhuis RA; Kirkels WJ; De Koning HJ; Kranse R; Nus HG; Blijenberg BG
    Int J Cancer; 1996 Jan; 65(2):145-51. PubMed ID: 8567109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
    Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
    Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
    Cao XL; Gao JP; Han G; Tang J; Hong BF
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.